Anirban Paul

Anirban Paul is an Associate Professor in the Department of Neuroscience and Experimental Therapeutics at Pennsylvania State University, affiliated with the Penn State Neuroscience Institute. His research focuses on cellular and molecular mechanisms of GABAergic inhibitory circuits, with particular emphasis on interneuron biology and its implications in neurological disorders.

Dr. Paul's research spans multiple neuroscience domains, with primary focus on GABAergic inhibitory circuits and interneuron biology. His work investigates how specific neuron subtypes, particularly Chandelier cells and cortical interneurons, contribute to brain function and dysfunction. He has made significant contributions to understanding the role of these cells in schizophrenia, Alzheimer's disease, and other neurological conditions. His research integrates molecular, cellular, and systems-level approaches to uncover fundamental mechanisms of neural circuit assembly, plasticity, and function. Key areas include RNA regulation in neuronal development, transcriptomic subtypes of inhibitory neurons, and cell-type specific vulnerabilities in neurodegenerative diseases.

His research portfolio demonstrates consistent productivity with publications spanning from 2003 to 2025, showing an evolving focus from basic molecular neuroscience to translational research in neurological disorders. Recent work emphasizes single-cell analysis techniques and the role of specific interneuron populations in disease mechanisms, particularly in schizophrenia and Alzheimer's disease. His publications appear in high-impact neuroscience journals including Neuron, BMC Biology, and Frontiers in Cellular Neuroscience.

Dr. Paul has received the NARSAD Young Investigator Award (2018), recognizing his promising research in neuroscience. His scientific contributions have been supported by multiple competitive grants from prestigious organizations including the National Institute on Aging (NIA) and the Brain and Behavior Research Foundation.

He serves as Principal Investigator on multiple active research projects, including two major grants from the National Institute on Aging focused on cell-type specific risk and resilience in Alzheimer's disease and aging (2021-2024 and 2024-2026), as well as previous projects from the Brain and Behavior Research Foundation investigating Chandelier cells in schizophrenia. His research program demonstrates sustained funding and scientific leadership in the field of interneuron biology and its clinical implications.